Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial

Mello, Marcelo Feijó de; Costa, Mariana Cadrobbi Pupo; Schoedl, Aline Ferri; Fiks, Jose Paulo

doi:10.1590/s1516-44462008000400011

Cited by 22 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In its limited use at the VAMC, aripiprazole had three failures and one partial response within a dosing range of 5.0–10.0 mg. A chart review of 27 treatment resistant veterans with military-related PTSD [99] and a 16-week open-label trial of aripiprazole 9.6 ± 4.3 mg/day with 32 civilians with PTSD recorded reduction of symptoms [100]. The aripiprazole dosing range in the latter study was relatively similar to that utilized by the VAMC clinicians.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Post-Traumatic Stress Disorder Nightmares at a Veterans Affairs Medical Center

Detweiler

Pagadala

Candelario

et al. 2016

JCM

View full text Add to dashboard Cite

The effectiveness of medications for PTSD in general has been well studied, but the effectiveness of medicatio.ns prescribed specifically for post-traumatic stress disorder (PTSD) nightmares is less well known. This retrospective chart review examined the efficacy of various medications used in actual treatment of PTSD nightmares at one Veteran Affairs Hospital. Records at the Salem, VA Veterans Affairs Medical Center (VAMC) were examined from 2009 to 2013 to check for the efficacy of actual treatments used in comparis.on with treatments suggested in three main review articles. The final sample consisted of 327 patients and 478 separate medication trials involving 21 individual medications plus 13 different medication combinations. The three most frequently utilized medications were prazosin (107 trials), risperidone (81 trials), and quetiapine (72 trials). Five medications had 20 or more trials with successful results (partial to full nightmare cessation) in >50% of trials: risperidone (77%, 1.0–6.0 mg), clonidine (63%, 0.1–2.0 mg), quetiapine (50%, 12.5–800.0 mg), mirtazapine (50%; 7.5–30.0 mg), and terazosin (64%, 50.0–300.0 mg). Notably, olanzapine (2.5–10.0) was successful (full remission) in all five prescription trials in five separate patients. Based on the clinical results, the use of risperidone, clonidine, terazosin, and olanzapine warrants additional investigation in clinically controlled trials as medications prescribed specifically for PTSD nightmares.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Post-Traumatic Stress Disorder Nightmares at a Veterans Affairs Medical Center

Detweiler

Pagadala

Candelario

et al. 2016

JCM

View full text Add to dashboard Cite

show abstract

“…Atypical antipsychotics: Some data suggest that the atypical antipsychotics, risperidone (Level 2) [1030], aripiprazole (Level 3) [1031,1032], and quetiapine (Level 3) [1034,1035] may be a useful alternative to SSRIs for some patients with PTSD. A meta-analysis of seven RCTs using atypical antipsychotics, either as monotherapy or adjunctively, concluded that these agents may be beneficial in the treatment of PTSD, particularly for the symptom of “intrusion” [1061].…”

Section: Posttraumatic Stress Disordermentioning

confidence: 99%

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders

et al. 2014

View full text Add to dashboard Cite

BackgroundAnxiety and related disorders are among the most common mental disorders, with lifetime prevalence reportedly as high as 31%. Unfortunately, anxiety disorders are under-diagnosed and under-treated.MethodsThese guidelines were developed by Canadian experts in anxiety and related disorders through a consensus process. Data on the epidemiology, diagnosis, and treatment (psychological and pharmacological) were obtained through MEDLINE, PsycINFO, and manual searches (1980–2012). Treatment strategies were rated on strength of evidence, and a clinical recommendation for each intervention was made, based on global impression of efficacy, effectiveness, and side effects, using a modified version of the periodic health examination guidelines.ResultsThese guidelines are presented in 10 sections, including an introduction, principles of diagnosis and management, six sections (Sections 3 through 8) on the specific anxiety-related disorders (panic disorder, agoraphobia, specific phobia, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, and posttraumatic stress disorder), and two additional sections on special populations (children/adolescents, pregnant/lactating women, and the elderly) and clinical issues in patients with comorbid conditions.ConclusionsAnxiety and related disorders are very common in clinical practice, and frequently comorbid with other psychiatric and medical conditions. Optimal management requires a good understanding of the efficacy and side effect profiles of pharmacological and psychological treatments.

show abstract

“…Two small RCTs of aripiprazole have been conducted in OCD with promising preliminary results (56, 57). In addition, open label trials of aripiprazole have been conducted in GAD, panic disorder (58), MDD with anxious features (59) and PTSD (60) with initial encouraging results. Additional randomized controlled data are required to further characterize the efficacy of aripirazole in anxiety disorders.…”

Section: Competitive Environmentmentioning

confidence: 99%

Emerging drugs for the treatment of anxiety

Murrough

Yaqubi

Sayed

et al. 2015

Expert Opinion on Emerging Drugs

133

View full text Add to dashboard Cite

Introduction Anxiety disorders are among the most prevalent and disabling psychiatric disorders in the United States and worldwide. Basic research has provided critical insights into the mechanism regulating fear behavior in animals and a host of animal models have been developed in order to screen compounds for anxiolytic properties. Despite this progress, no mechanistically novel agents for the treatment of anxiety have come to market in more than two decades. Areas covered The current review will provide a critical summary of current pharmacological approaches to the treatment of anxiety and will examine the pharmacotherapeutic pipeline for treatments in development. Anxiety and related disorders considered herein include panic disorder, social anxiety disorder, generalized anxiety disorder and posttraumatic stress disorder. The glutamate, neuropeptide and endocannabinoid systems show particular promise as future targets for novel drug development. Expert opinion In the face of an ever-growing understanding of fear related behavior, the field awaits the translation of this research into mechanistically novel treatments. Obstacles will be overcome through close collaboration between basic and clinical researchers with the goal of aligning valid endophenotypes of human anxiety disorders with improved animal models. Novel approaches are needed to move basic discoveries into new, more effective treatments for our patients.

show abstract

Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial

Cited by 22 publications

References 11 publications

Treatment of Post-Traumatic Stress Disorder Nightmares at a Veterans Affairs Medical Center

Treatment of Post-Traumatic Stress Disorder Nightmares at a Veterans Affairs Medical Center

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders

Emerging drugs for the treatment of anxiety

Contact Info

Product

Resources

About